nct_id,endpoint_name,endpoint_type,endpoint_group_id,endpoint_group_title_raw,endpoint_group_desc_raw,endpoint_group_title_norm,endpoint_group_desc_norm,matched_arm_id,arm_group_title_raw,arm_group_desc_raw,arm_group_title_norm,arm_group_desc_norm,match_type,title_score,desc_score,debug_notes,top_candidates_json
NCT01673867,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint,Primary,O1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 61}, {""arm_id"": ""NCT01673867_A1"", ""arm_group_title_raw"": ""Arm A: Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 39}]"
NCT01673867,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint,Primary,O2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 73}, {""arm_id"": ""NCT01673867_A2"", ""arm_group_title_raw"": ""Arm B: Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 33}]"
NCT01673867,Objective Response Rate (ORR),Key Secondary,O1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",nivolumab,nivolumab 3 mg kg solution administered intravenously every 2 weeks eligible participants transitioned to nivolumab 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 61}, {""arm_id"": ""NCT01673867_A1"", ""arm_group_title_raw"": ""Arm A: Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 39}]"
NCT01673867,Objective Response Rate (ORR),Key Secondary,O2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,NCT01673867_P2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",docetaxel,docetaxel 75mg m 2 solution administered intravenously every 3 weeks eligible participants transitioned to nivolumab 3 mg kg every 2 weeks or 480 mg every 4 weeks participants treated until disease progression discontinuation due to toxicity withdrawal of consent or end of study,precise_title,100,100,,"[{""arm_id"": ""NCT01673867_P2"", ""arm_group_title_raw"": ""Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT01673867_P1"", ""arm_group_title_raw"": ""Nivolumab"", ""arm_group_desc_raw"": ""Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study."", ""title_score"": 22, ""desc_score"": 73}, {""arm_id"": ""NCT01673867_A2"", ""arm_group_title_raw"": ""Arm B: Docetaxel"", ""arm_group_desc_raw"": ""Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends."", ""title_score"": 75, ""desc_score"": 33}]"
